In the past two years, IU Health has laid off 935 people, halted construction of a major bed tower, sold off health clinics and decided to close its proton-therapy center. But there are three more years of changes to come, said CFO Ryan Kitchell.
Major Health Partners will construct the new hospital on the north edge of Shelbyville, after nearly a decade of shifting services to that location. Construction could begin next month.
Drugmakers, including Eli Lilly and Co., should conduct new trials to assess the heart risks of testosterone therapies used by millions of men last year, advisers to U.S. regulators said.
Community executives said the investment and projects, which will begin this fall and extend over several years, prove their long-term commitment to the east side of the city.
Testosterone supplements used last year by about 2.3 million men are spurring debates over how necessary and safe they may be, even as U.S. regulators consider approving a new product.
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
Eli Lilly and Co. executives on Friday repeated their plea to local businesses to support early childhood education, highlighting the work force development and crime-reduction benefits associated with the effort.
Eli Lilly and Co. said Friday its potential colorectal cancer drug Cyramza helped patients on chemotherapy with advanced cases of the disease survive longer than patients on chemotherapy alone.
European regulators have approved a long-lasting insulin from Eli Lilly and Co. and German drugmaker Boehringer Ingelheim that is the subject of patent-infringement litigation with French rival Sanofi.
The Indianapolis-based drugmaker said Thursday that peglispro produced statistically significant lower blood sugar levels in patients when compared to people who took the Sanofi insulin Lantus in two late-stage studies of people with type 1 diabetes.
Just three months before the parent company of AIT Laboratories was sold in 2009 to its employees for $90 million, it was appraised for $17.1 million, according to a U.S. Department of Labor lawsuit.
Takeda Pharmaceutical Co. and Eli Lilly and Co. lost a bid to have a judge throw out a combined $9 billion punitive-damage award over claims the drugmakers hid the cancer risks of their Actos diabetes medicine.
The Indiana Blood Center is set to lose more than one-third of its revenue early next year, as three hospital systems bolt for cheaper prices offered by the American Red Cross.
Franciscan Alliance, which operates three hospitals in the Indianapolis area, is seeing fewer patients this year but is making more money due to expense cuts.
Rural/Metro Corp. says the changing health care landscape and the challenges of covering rural communities are forcing it to end its area ambulance services. It’s also closing a billing operations center in Indianapolis.
Final approval could be delayed until mid-2016 due to a claim of patent infringement by drugmaker Sanofi.
A subsidiary of Dublin, Ohio-based Cardinal Health Inc. is seeking tax breaks from the city of Indianapolis to help it open a $14.4 million local drug-production facility that would employ 85 workers by 2017.
The rising threat from drug-resistant germs and increasing calls from global health groups for more potent antibiotics is placing a premium on companies such as Cubist. The $4.8 billion drug developer is preparing to introduce four new medicines by 2020.
The plant closure will affect 23 plant employees, all of whom will be offered comparable positions at a Lilly plant near Clinton that employs about 500 workers.
Bloomington’s Monroe Hospital, which has had a close relationship with Indianapolis-based St. Vincent Health, filed for bankruptcy reorganization on Friday and plans to sell its business to a Canadian operator.
